Tecentriq atezolizumab regulatory update

FDA granted accelerated approval to Tecentriq atezolizumab from Roche’s Genentech unit to treat locally advanced or metastatic urothelial carcinoma that has progressed on or

Read the full 242 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE